醋酸氟卡胺结构式
|
常用名 | 醋酸氟卡胺 | 英文名 | flecainide acetate |
---|---|---|---|---|
CAS号 | 54143-56-5 | 分子量 | 474.395 | |
密度 | 1.286g/cm3 | 沸点 | 434.9ºC at 760mmHg | |
分子式 | C19H24F6N2O5 | 熔点 | 145-147℃ | |
MSDS | 中文版 美版 | 闪点 | 216.8ºC | |
符号 |
GHS07, GHS08 |
信号词 | Danger |
醋酸氟卡胺用途Flecainide(Tambocor)能阻断位于心脏的Nav1.5钠离子通道,能抗心律失常。 |
中文名 | 醋酸氟卡尼 |
---|---|
英文名 | flecainide acetate |
中文别名 | 乙酸氟卡尼 | 醋酸氟卡胺 |
英文别名 | 更多 |
描述 | Flecainide(Tambocor)能阻断位于心脏的Nav1.5钠离子通道,能抗心律失常。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.286g/cm3 |
---|---|
沸点 | 434.9ºC at 760mmHg |
熔点 | 145-147℃ |
分子式 | C19H24F6N2O5 |
分子量 | 474.395 |
闪点 | 216.8ºC |
精确质量 | 474.158936 |
PSA | 96.89000 |
LogP | 4.25130 |
储存条件 | 2-8°C |
水溶解性 | Soluble in water and in anhydrous ethanol. It is freely soluble in dilute acetic acid and practically insoluble in dilute hydrochloric acid. |
符号 |
GHS07, GHS08 |
---|---|
信号词 | Danger |
危害声明 | H302-H315-H319-H335-H360 |
警示性声明 | P201-P280-P301 + P312 + P330-P305 + P351 + P338-P308 + P313 |
危害码 (欧洲) | Xn |
风险声明 (欧洲) | R22 |
安全声明 (欧洲) | 22-26-36/37/39-45 |
危险品运输编码 | UN 3249 |
WGK德国 | - |
RTECS号 | CV5792550 |
包装等级 | III |
危险类别 | 6.1(b) |
~87% 醋酸氟卡胺 54143-56-5 |
文献:"Joint Stock Company Grindeks" Patent: EP1918280 A1, 2008 ; Location in patent: Page/Page column 4; 8 ; |
~87% 醋酸氟卡胺 54143-56-5 |
文献:Geneva Pharmaceuticals, Inc. Patent: US6458957 B1, 2002 ; |
~87% 醋酸氟卡胺 54143-56-5 |
文献:Wang, Zhi-Xian; Li, Yuanqiang; Guntoori, Bhaskar Reddy Patent: US2005/59825 A1, 2005 ; Location in patent: Page/Page column 4 ; |
醋酸氟卡胺上游产品 3 | |
---|---|
醋酸氟卡胺下游产品 0 |
Multiple modes of ryanodine receptor 2 inhibition by flecainide.
Mol. Pharmacol. 86(6) , 696-706, (2014) Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodine receptors (RyR2), calsequestrin, or calmodulin. Flecainide, a class I ant... |
|
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity.
Drug Metab. Pharmacokinet. 30 , 257-62, (2015) The aims of this study were to clarify whether the ratio of S- to R-flecainide (S/R ratio) in the serum flecainide concentration was associated with the stereoselectivity of flecainide metabolism, and... |
|
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)
|
FLECAINIDE MONOACETATE |
acetic acid,N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide |
R 818 |
Flecainide acetate salt |
acide acétique - N-(pipéridin-2-ylméthyl)-2,5-bis(2,2,2-trifluoroéthoxy)benzamide (1:1) |
N-(Piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide acetate (1:1) |
EINECS 258-997-5 |
Flecainide acetate |
N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide acetate (1:1) |
N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt |
UNII:M8U465Q1WQ |
N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide acetate |
Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, acetate (1:1) |
N-(Piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluorethoxy)benzolcarboxamidacetat |
Flecainide (acetate) |